Business Context and Reporting Period
Company: Ingevity Corp (NGVT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Ingevity provides products and technologies to purify, protect, and enhance the world, operating in three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies. The company is currently executing a significant repositioning of its Performance Chemicals segment to reduce exposure to lower-margin industrial markets and transition away from crude tall oil (CTO) dependency.
Key Financial Metrics
| Metric (in millions) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales | $390.6 | $481.8 | $730.7 | $874.4 |
| Gross Profit | $123.2 | $153.0 | $222.9 | $283.4 |
| Gross Margin | 31.5% | 31.8% | 30.5% | 32.4% |
| Net Income (Loss) | $(283.7) | $35.5 | $(339.7) | $86.2 |
| Diluted EPS | $(7.81) | $0.97 | $(9.36) | $2.33 |
| Adjusted EBITDA (Non-GAAP) | $101.3 | $120.7 | $175.7 | $224.6 |
| Cash from Operations (YTD) | $17.6 | $53.7 | — | — |
| Total Debt (incl. leases) | $1,508.8 | — | — | — |
| Cash & Equivalents | $107.4 | — | — | — |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 19% in Q2 and 16% YTD compared to 2023. The decline was driven primarily by volume reductions in the Performance Chemicals segment (specifically Industrial Specialties) due to strategic repositioning and unfavorable weather impacting Road Technologies.
- Goodwill Impairment: A non-cash goodwill impairment charge of $349.1 million was recorded in Q2 2024, representing 100% of the goodwill in the Performance Chemicals reporting unit. This was triggered by higher-than-forecasted CTO costs and depressed industrial volumes.
- Restructuring Charges: Total restructuring and other charges were $13.1 million in Q2 and $75.9 million YTD. This includes significant asset disposal charges and accelerated depreciation/amortization related to the Performance Chemicals repositioning.
- CTO Resale Losses: The company incurred $23.5 million in Q2 and $50.0 million YTD in losses from reselling excess crude tall oil (CTO) volumes. These losses are recorded in "Other (income) expense, net."
- Segment Performance:
- Performance Materials: Sales increased 9% and EBITDA increased 28% due to higher automotive carbon volumes and lower input costs.
- Performance Chemicals: Sales decreased 35% and EBITDA turned negative ($-1.3 million YTD) due to volume declines and elevated CTO costs.
- Advanced Polymer Technologies: Sales decreased 10% due to pricing pressure, partially offset by volume gains.
Guidance, Outlook, and Risks
- 2024 Full Year Outlook:
- Net Sales: Expected between $1.40 billion and $1.50 billion.
- Adjusted EBITDA: Expected between $350 million and $360 million.
- Strategic Actions & Subsequent Events:
- CTO Contract Termination: On July 1, 2024, the company terminated its long-term CTO supply agreement with Georgia-Pacific. This required a $50 million cash payment immediately and another $50 million by October 15, 2024. This ends the obligation to purchase excess CTO volumes.
- Crossett Plant Closure: Announced July 31, 2024, the closure of the Crossett, Arkansas facility is expected to incur ~$100 million in aggregate charges (mostly non-cash) but will yield $20-$25 million in annual operational savings starting in 2025.
- Liquidity: The company maintains $241.7 million in undrawn capacity under its revolving credit facility. Management expects cash flow from operations, cash on hand, and credit facility availability to fund operations for the next 12 months.
- Legal Contingency: A $85.0 million liability (trebled antitrust verdict) related to BASF litigation remains accrued. The company is appealing the verdict.
- Risks: Key risks include the execution of plant closures, continued volatility in CTO pricing, adverse weather impacting road technologies, and global economic conditions affecting industrial demand.
Investor Verification Checklist
- Impairment Assumptions: Verify the specific assumptions (discount rates, growth rates) used in the $349.1 million goodwill impairment analysis for the Performance Chemicals segment.
- Restructuring Cash Impact: Confirm the timing and amount of remaining cash outflows for the Performance Chemicals repositioning ($65 million expected cash charges total) and the Crossett closure.
- CTO Contract Termination Costs: Monitor the execution of the second $50 million payment to Georgia-Pacific and the cessation of CTO resale losses.
- Debt Covenants: Review compliance with the 4.0x net leverage ratio and 3.0x interest coverage ratio, noting the current leverage is 3.3x and coverage is 4.8x.
- Legal Proceedings: Track the status of the BASF appeal and potential additional interest or fee accruals on the $85 million judgment.